Tyrosine kinase inhibitors as cancer therapy (Q35589206)

9 August 2017

1 reference

title

Tyrosine kinase inhibitors as cancer therapy (English)

1 reference

9 August 2017

Gwen L Nichols

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

758-771

1 reference

Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping, and transcriptional analysis of c-src and flanking regions

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Switching signals on or off by receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

SH2/SH3 signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The PTB domain: a new protein module implicated in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Oncogenic activation of tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Oncogenic activation of the ret protooncogene in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

c-kit Point mutation in patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Amplification of a novel v-erbB-related gene in a human mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

c-erbB-2 in breast cancer: development of a clinically useful marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Kinase inhibitors in cancer therapy: a look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Clinical implications of circulating angiogenic factors in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Expression of bFGF and VEGF in brain astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Development of inhibitors for protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Clinical trials of Herceptin(trastuzumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023774

21 January 2018

Identifiers

DOI

10.1081/CNV-120023774

1 reference

9 August 2017

1 reference